BioPharma Resources

Investigational drug · Phase 2

PCV15

Also called: 15-valent pneumococcal conjugate vaccine

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pneumococcal Disease.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

8

Any phase or sponsor naming "PCV15"

First trial start

2024

Jul 25, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "PCV15", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Pneumococcal Disease

Largest trials

Live from ClinicalTrials.gov: studies naming "PCV15" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 324 on PubMed

Also in development for Pneumococcal Disease

  • PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease

  • PG4Phase 35 trials

    Pfizer · Pneumococcal Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.